

**Molecular Cell, Volume 71**

**Supplemental Information**

**An Antiviral Branch of the IL-1 Signaling Pathway**

**Restricts Immune-Evasive Virus Replication**

**Megan H. Orzalli, Avi Smith, Kellie A. Jurado, Akiko Iwasaki, Jonathan A. Garlick, and Jonathan C. Kagan**

**An antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication.**

Megan H. Orzalli<sup>1</sup>, Avi Smith<sup>2</sup>, Kellie A. Jurado<sup>3,4</sup>, Akiko Iwasaki<sup>3,4</sup>, Jonathan A. Garlick<sup>2,5</sup>, and Jonathan C. Kagan<sup>1,6,7</sup>

<sup>1</sup>Division of Gastroenterology, Boston Children's Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA

<sup>2</sup>Department of Diagnostic Sciences, Tufts University School of Dental Medicine, 1 Kneeland St, Boston, MA 02111, USA

<sup>3</sup>Howard Hughes Medical Institute, New Haven, CT 06519, USA

<sup>4</sup>Department of Immunobiology, Yale University, New Haven, CT 06519, USA

<sup>5</sup>Sackler Graduate School of Biomedical Sciences, Tufts University, 136 Harrison Avenue, Boston, MA 02111, USA

<sup>6</sup>Corresponding Author: [jonathan.kagan@childrens.harvard.edu](mailto:jonathan.kagan@childrens.harvard.edu)

<sup>7</sup>Lead Contact

**Supplemental Figures and Legends  
Figures S1-S6.**

Figure S1





Figure S2

A.



B.






Figure S3


A.



B.



C.



D.




Figure S4




Figure S5






Figure S6





### Supplemental Figure Legends.

**Figure S1. Antiviral transcriptional responses are specific to IL-1 subfamily cytokines, Related to Figure 2.** HFFs (A) and NOKs (B) were stimulated with IL-1 $\beta$  (10 ng/ml), IL-36 $\alpha$  (10 ng/ml), or IL-33 (10 ng/ml). Total cellular RNA was harvested at 6 h and quantified by qRT-PCR for *RSAD2* and *CXCL8* transcript abundance. C) HFF (*left*) and NOKs (*right*) were stimulated with IL-1 $\beta$  (10 ng/ml) or IL-18 (10 ng/ml) and *CXCL8* abundance was determined by qRT-PCR at 6 h. (A-C) Data are normalized to *GAPDH*. Data are an average of three independent experiments +/- SEM. Student's t test;  $p < 0.05$ ,  $**p < 0.01$ .

**Figure S2. IL-1 treatment inhibits viral protein accumulation in VSV-infected cells, Related to Figure 4.** A) HFFs were mock-infected or infected with wt VSV at a MOI of 0.1 in the presence or absence of IL1 $\beta$  (10 ng/ml). Cells were fixed and stained for VSV M protein and RSAD2 at 24 hpi using specific antibodies. Nuclei were counterstained with DRAQ5. Scale bar 10  $\mu$ m. B) Two-hundred cells in each condition were examined for VSV M and RSAD2 protein. VSV M and RSAD2 positive cells are presented as a percentage of the total number of cells examined. Scale bar 10  $\mu$ m. Results are the average of three-independent experiments +/- SEM. Student's t test;  $p^{***} < 0.001$ ,  $****p < 0.0001$ .

**Figure S3. TNF receptor signaling is not required for IL-1 mediated antiviral transcriptional responses, Related to Figure 6.** (A-B) HFFs were transfected with ctrl siRNAs or siRNAs targeting *IRF1*, *TNFR1*, or *TRADD* for 72 h. A) The efficiency of siRNA-mediated depletion of indicated transcripts was demonstrated by qRT-PCR. B) siRNA-transfected cells were then treated with (left) IL-1 $\alpha$  (100 pg/ml) or (right) TNF $\alpha$  (100 pg/ml) and total cellular RNA was isolated at 6 h. *RSAD2* and *CXCL8* transcripts were quantified by qRT-PCR and normalized to *GAPDH*. C) HFFs were stimulated with IL-1 $\beta$  (10 ng/ml) for 24 h. Cell free supernatants were isolated and analyzed by ELISA for TNF $\alpha$  and CXCL8 protein. D) HFFs were stimulated with IL-1 $\beta$  (10 ng/ml)

and total cellular RNA was isolated at 0, 3, and 6 h. Transcript abundance was determined by nCounter and normalized to *GAPDH*. Data are an average of three-independent experiments +/- SEM. Student's t test;  $p^* < 0.05$ ,  $p^{**} < 0.01$   $p^{***} < 0.001$

**Figure S4. IFNAR signaling is not required for IL-1 mediated antiviral responses, Related to Figure 6.** A) HFFs were pre-treated with indicated antibodies (20  $\mu\text{g/ml}$ ) for 1 h prior to dilution with an equal volume of control media or media containing IL-1 $\alpha$  (200  $\text{pg/ml}$ ) or IFN $\beta$  (2 U/ml or 20 U/ml). The final concentration of IL-1 $\alpha$  and IFN $\beta$  were 100  $\text{pg/ml}$  and 1 U/ml or 10 U/ml, respectively. B) Control fibroblasts (C1) or fibroblasts isolated from patients with mutations in *IFNAR1* (P1) were treated with IL-1 $\alpha$  (100  $\text{pg/ml}$ ) or IFN $\beta$  (10 U/ml). Total cellular RNA was isolated at 6 h post-stimulation and analyzed by qRT-PCR for indicated transcripts. C) Control (C1) or patient (P1) fibroblasts were infected with VSV (MOI 0.1) in the presence of IL-1 $\alpha$  (100  $\text{pg/ml}$ ). Infected-cell supernatants were isolated at 48 hpi and analyzed by plaque assay. Data are the average of at least three independent experiments +/- SEM. Student's t test  $*p < 0.05$ ,

**Figure S5. IRF2 protein abundance is reduced in fibroblasts transduced with CRISPR/Cas9 lentivirus constructs, Related to Figure 7.** hTERT-HFFs transduced with lentiviruses expressing Cas9 alone or in combination with indicated guide RNAs were fixed and examined by A) immunofluorescence or B) flow cytometry for IRF2 protein abundance. Scale bar 10  $\mu\text{m}$ .

**Figure S6. Model of the antiviral signaling pathway induced by IL-1 cytokines. Related to Figures 1-7.** (*left*) Keratinocytes infected with non-immune evasive viruses transcriptionally upregulate IFNs, which act in an autocrine or paracrine manner to induce ISGs and restrict virus replication. By contrast, infection of keratinocytes with viruses that suppress IFN expression (*right*) results in release of pre-stored IL-1 cytokines. IL-1 cytokines stimulate fibroblasts to induce IRF1 transcriptional activity and expression of an antiviral factor. This factor may signal through gp130

on fibroblasts to activate STAT1 and initiate ISG expression. The ability of IRF1 to regulate this signaling pathway is inhibited by IRF2.